TARO Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Company profile

TARO stock data



17 Jun 21
2 Aug 21
31 Mar 22
Quarter (USD)
Mar 21 Mar 20 Mar 19 Mar 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 21 Mar 20 Mar 19 Mar 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 77 83 -7.2%
Opened positions 9 17 -47.1%
Closed positions 15 10 +50.0%
Increased positions 24 26 -7.7%
Reduced positions 23 22 +4.5%
13F shares
Current Prev Q Change
Total value 716.46M 369.03M +94.1%
Total shares 4.76M 5.03M -5.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 753.1K $55.54M -4.1%
FMR 623.92K $46.01M -8.1%
Krensavage Asset Management 547.64K $40.39M -1.1%
Dimensional Fund Advisors 502.49K $37.06M +4.9%
Brandes Investment Partners 405.47K $30.33M -1.6%
Acadian Asset Management 351.09K $25.9M -4.7%
BLK Blackrock 186.04K $13.72M +23.4%
Eversept Partners 164.38K $12.12M +8.0%
IVZ Invesco 161.8K $11.93M +6.3%
Hotchkis & Wiley Capital Management 109.55K $8.08M +8.5%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -118.75K EXIT
NTRS Northern Trust 98.76K -99.78K -50.3%
FMR 623.92K -54.82K -8.1%
ARK Investment Management 78.63K +50.61K +180.6%
Nuveen Asset Management 54.46K +40.04K +277.6%
Charles Schwab Investment Management 0 -38.54K EXIT
BLK Blackrock 186.04K +35.26K +23.4%
Renaissance Technologies 753.1K -32K -4.1%
MS Morgan Stanley 15.03K -27.69K -64.8%
Dimensional Fund Advisors 502.49K +23.5K +4.9%

Financial report summary

Content analysis
H.S. freshman Avg
New words: Accessible, Agarwal, Analyst, anesthesiologist, Aquinox, Arab, bellwether, Butalbital, certainty, CFA, chairperson, Chester, Cloderm, commerce, DOJ, Doxepin, East, entrepreneurial, essence, Fioricet, Flame, Florida, GC, heard, illegitimate, INSEAD, inserted, interstate, Michigan, Microbiology, Middle, MIGDALINSURANCE, MiMedx, misreporting, Moscow, municipal, Muscat, Neoleukin, nitrosamine, nurse, Polypid, quarantine, Ram, relocation, renowned, Scalp, scrutinize, Sernivo, simplifying, simultaneously, Sinequan, Sklice, span, Sri, St, stay, stint, subsidize, suspect, Taclonex, Tavaborole, twenty, Victoria, Vikash, Zyclara
Removed: Accenture, bb, bearing, began, Belgium, Benzoyl, BLA, calcium, career, Chantal, claimed, Clindamycin, codification, consulting, controversy, Dapsone, depreciate, disposed, dissolved, exportation, formally, gel, Glaze, grand, GSK, Hospira, IBM, Ikaria, inspector, Investigative, involvement, Ireland, Irish, jury, Kempac, LeBlanc, Mallinckrodt, manifested, modulator, Montreal, Mylan, negotiated, Peroxide, Phosphate, Polylab, positively, projected, promissory, recourse, reorganize, repealed, Rich, Richard, sovereign, subpoena, ULC, unfold, unutilized, vision


No filings